echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NSCLC backline refractory? Sulfatinib is expected to break the dilemma or bring new dawn to patients| 2022 ESMO

    NSCLC backline refractory? Sulfatinib is expected to break the dilemma or bring new dawn to patients| 2022 ESMO

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    *For medical professionals only

    2022 ESMO Sulfatinib new attempts, results at a glance



    "Standard" treatment regimens for epNETs and pNETs


    ——New exploration of sofotinib



    Zheng Yanfang

    Professor, Chief Physician, Doctoral Supervisor


    • Director of the Department of Oncology, Affiliated Cancer Hospital of Guangzhou Medical University
    • Director of the Department of Oncology, Affiliated Cancer Hospital of Guangzhou Medical University;
    • Distinguished Professor of "Nanshan Scholar" of Guangzhou Medical University;
    • Chairman of the Tumor Biological Therapy Committee of Guangdong Association of Integrative Traditional and Western Medicine;
    • Chairman-elect of Tumor Targeted Therapy Technology Branch of Chinese Society of Biomedical Engineering;
    • Executive Vice President and Secretary General of Guangdong Society of Cell Biology;
    • Vice Chairman of the Biological Therapy Professional Committee of Guangdong Anti-Cancer Society;
    • Vice Chairman of the Special Committee of Integrated Traditional Chinese and Western Medicine of Guangdong Primary Medicine Association;
    • Vice Chairman of lung cancer committee of Guangdong Primary Medicine Association;
    • Vice Chairman of Lung Cancer and Lung Metastases Professional Committee of Guangdong Association of Clinical Medicine;
    • Member of the American Medical Association and the American Federation of Physicians;
    • Physician practicing in the United States, postdoctoral fellow in the United States


    References:

    Zeng Lei,Yang Kaixuan.


    [2] Xu J,Shen L,Zhou Z,et al.


    [3] Xu J,Shen L,Bai C,et al.


    [4] Yanfang Zheng,Feiyu Niu,Peng Jiang,et al.




    This information is supported


    This material is intended to facilitate the communication and exchange



    NP-STD-22N70-Valid Until 2024 Sep

    *The medical profession strives to ensure that the published content is accurate and reliable at the time of approval, but does not make any promises and guarantees as to the timeliness of the published content, as well as the accuracy and completeness of the cited information (if any), nor does it assume any responsibility
    for any situation arising from the fact that the content is outdated, and the referenced information may be inaccurate or incomplete.

    Parties are requested to verify
    separately when adopting or using this as a basis for decision-making.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.